The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Considers Tanezumab Application for Chronic OA Pain

FDA Considers Tanezumab Application for Chronic OA Pain

April 20, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In March, the U.S. Food & Drug Administration (FDA) accepted a Biologics License Application for a 2.5 mg dose of subcutaneous tanezumab, an investigational monoclonal antibody.1 The agent is being evaluated for treating patients with chronic pain due to moderate to severe osteoarthritis (OA) who have experienced inadequate relief with other analgesics.

You Might Also Like
  • Tanezumab for OA Pain
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Tanezumab’s Phase 3 Results for OA
Explore This Issue
May 2020
Also By This Author
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA

A non-opioid agent, tanezumab is in a new class of growth factor inhibitors that selectively targets, binds and inhibits nerve growth factor. Nerve growth factor levels increase after an injury and inflammation, as well as in patients with chronic pain. The treatment works differently from opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics, with its novel mechanism of action occurring in the periphery. Tanezumab inhibits pain signals produced in the muscles, skin and organs from reaching the spinal cord and brain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The press release noted herein makes no reference to the safety issues raised in clinical trials with nerve growth factor inhibitors. In one Phase 3 clinical trial with tanezumab reported at ACR in November 2019, randomized patients (n=2,996) who received at least one dose of tanezumab were evaluated for safety and efficacy (abstract 2756).2 Tanezumab-treated patients had higher rates of progressive osteoarthritis type 1 (RPOA1), subchondral insufficiency fracture (SIF) and total joint replacement (TJR) than did patients treated with NSAIDs.

In a study by Schnitzer et al., tanezumabtreated patients also had higher rates of SIF and TJR than patients blindly treated with placebo.3 However, these patients had statistically significant improvements in pain scores (WOMAC-Pain) and physical function (WOMAC-Physical Function), as well as statistically significant improvements in patient global assessment of osteoarthritis (PGA-OA).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Earlier tanezumab trials suggested patients using concomitant NSAIDs had more rapidly progressive OA and TJR.4 Due to these findings, clinical trials were put on hold. Once the hold was lifted, subsequent clinical trials included a plan that excluded patients from taking concomitant NSAIDs, removed higher tanezumab doses that had not shown benefit over lower doses and also excluded patients with risk factors for, or who had evidence of, RPOA, SIF or avascular necrosis.

Newer studies consistently showed that tanezumab is an effective analgesic, but that patients have a higher propensity to develop rapidly progressive OA and have an increased need for TJR. For patients trying to avoid joint replacement but improve pain management, tanezumab would not likely be optimal OA management. Because of these safety issues, it seems as though, if approved by the FDA, a REMS strategy may be needed to ensure the risks and benefits of treatment are clear to prescribers and patients.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: Chronic pain, FDA, osteoarthritis (OA), Pain, Pain Management, tanezumab, U.S. Food and Drug Administration (FDA)Issue: May 2020

You Might Also Like:
  • Tanezumab for OA Pain
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Tanezumab’s Phase 3 Results for OA
  • Lilly Says New Type of Pain Drug Could Reduce Need for Opioids

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.